πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

111 results for β€œChongqing” Clear

  1. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial
  2. pCAR-19B cells

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials
  3. A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

    Chongqing Precision Biotech Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial
  4. Anti-CD123 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    AML (Acute Myeloid Leukemia)

    phase 1 small molecule active

    1 trial
  5. Anti-CD19 UCAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Dermatomyositis, Juvenile

    phase 1 small molecule active

    1 trial
  6. Anti-CD5 CAR NK cells

    Chongqing Precision Biotech Co., Ltd

    T-ALL/Lymphoma

    phase 1 mab active

    1 trial
  7. BCMA/CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  8. BCMA/CD70-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis (JDM)

    phase 1 mab active

    1 trial
  9. BGM-2121

    Chongqing Precision Biotech Co., Ltd

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial
  10. C-4-29 Cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma in Relapse

    phase 1 mab active

    1 trial
  11. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial
  12. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial
  13. CD19 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    SLE (Systemic Lupus)

    phase 1 mab active

    1 trial
  14. CD19-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis

    phase 1 mab active

    1 trial
  15. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials
  16. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial
  17. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial
  18. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial
  19. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial
  20. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial
  21. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial
  22. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial
  23. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial
  24. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources